1.Significance of Non-erosive Minimal Esophageal Lesions in Gastro-esophageal Reflux Disorder.
Sung Pyo HONG ; Pil Won PARK ; Seong Gyu HWANG ; Kwang Hyun KO ; Sun Young KWAK ; Se Hyun KIM ; Kye Sook KWON ; Yong Woon SHIN ; Ji Kon RYU ; Kwang Hyun RYU ; Sang Jong PARK ; Wook Hee WON ; Hyo Min YOO ; Hyung Mee BAE ; Min Jung PARK ; Yeol Keun WOO ; Kyung Chul KIM ; Kyung Hee KIM ; Seon Hwa NA ; Jung Wan KIM
The Korean Journal of Internal Medicine 2004;19(2):93-98
BACKGROUND: Non-erosive reflux disorder, which represents more than 60% of gastro-esophageal reflux disorders, lacks objective parameters for diagnosis. The purpose of this study was to evaluate the correlation between non-erosive minimal lesions at the lower esophagus and gastro-esophageal reflux disorder. METHODS: Patients were asked to answer a symptom questionnaire. The endoscopic findings were either graded by LA classification or recorded as non-erosive minimal lesions. Patients with minimal lesions were treated with rabeprazole or a placebo and responses were evaluated at weeks 1 and 4. RESULTS: In 8 centers, 3454 patients were screened. In patients with heartburn or acid regurgitation as the most bothersome symptom, 23.7% had endoscopy negative reflux disorder, 40.1% showed minimal lesions, and 36.2% had mucosal break esophagitis. Thirty-four percent of patients with minimal lesions and 39.1% of patients with LA 'grade A' mild esophagitis reported typical reflux symptoms as their main symptom. In patients with minimal lesions, medication with rabeprazole reduced symptoms significantly at weeks 1 and 4, but not with the placebo. CONCLUSION: Patients with non-erosive minimal esophageal lesions had similar reflux symptoms comparable to those with mild erosive reflux esophagitis, and reflux symptoms were improved with a short-term proton pump inhibitor. Thus, non-erosive minimal esophageal lesion constitutes a great part of gastro-esophageal reflux disorder.
2-Pyridinylmethylsulfinylbenzimidazoles
;
Adult
;
Aged
;
Aged, 80 and over
;
Anti-Ulcer Agents/*therapeutic use
;
Benzimidazoles/*therapeutic use
;
Enzyme Inhibitors/*therapeutic use
;
Esophageal Diseases/*pathology
;
Female
;
Follow-Up Studies
;
Gastroesophageal Reflux/drug therapy/epidemiology/*pathology
;
Humans
;
Korea/epidemiology
;
Male
;
Middle Aged
;
Omeprazole/*analogs & derivatives/therapeutic use
;
Prospective Studies
;
Proton-Translocating ATPases/*antagonists & inhibitors
;
Treatment Outcome